Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LV20.19 CAR-T cells |
Trade Name | |
Synonyms | Autologous CAR-20/19-T cells|4-1BB-CD3zeta LV20.19 CAR T cells |
Drug Descriptions |
LV20.19 CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) comprising single chain variable fragments targeting CD19 and CD20 coupled to CD3zeta and TNFRSF9 (CD137; 4-1BB) signaling domains, which potentially induce antitumor activity (PMID: 33020647, NCI Drug Dictionary). |
DrugClasses | CD19 Immune Cell Therapy 65 CD20 Immune Cell Therapy 13 |
CAS Registry Number | NA |
NCIT ID | C143156 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
LV20.19 CAR-T cells | LV20.19 CAR-T cells | 0 | 0 |
LV20.19 CAR-T cells + Pirtobrutinib | LV20.19 CAR-T cells Pirtobrutinib | 0 | 1 |